

International Textbook of Diabetes Mellitus, 4th Ed., Chapter 9 – Neuropeptides and Islet Hormone Secretion

References:

1. Ahrén B: Autonomic regulation of islet hormone secretion: implications for health and disease. *Diabetologia* 2000;43:393 – 410.
2. Kirchgessner AL, Gershon MD: Innervation and regulation of the pancreas by neurons in the gut. *Zeitschrift für Gastroenterologie. Verhandlungsband* 1991;26:230 – 233.
3. Ahrén B, Holst JJ: The cephalic insulin response to meal ingestion in humans is dependent both on cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. *Diabetes* 2001;50:1030 – 1038.
4. Taborsky GJ, Jr., Munding TO: Minireview: The role of the autonomic nervous system in mediating the glucagon response to hypoglycemia. *Endocrinology* 2012;153:1055 – 1062.
5. Gromada J, Hughes TE: Ringing the dinner bell for insulin: muscarinic M3 receptor activity in the control of pancreatic beta cell function. *Cell Metabolism* 2006;3:390 – 392.
6. Gilon P, Henquin JC: Mechanisms and physiological significance of cholinergic control of pancreatic beta-cell function. *Endocrine Reviews* 2001;22:565 – 604.
7. Kong KC, Butcher AJ, McWilliams P, et al.: M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1. *PNAS* 2010;107: 21181 – 21186.
8. Ruiz de Azua I, Gautam D, Jain S, et al.: Critical metabolic roles of β -cell M3 muscarinic acetylcholine receptors. *Life Sciences* 2012;91(21 – 22):986 – 991.
9. Ahrén B, Taborsky GJ, Jr.: The mechanism of vagal nerve stimulation of glucagon and insulin secretion in the dog. *Endocrinology* 1986;118:1551 – 1557.
10. Knuthsen S, Holst JJ, Baldissera FG, et al.: Gastrin-releasing peptide in the porcine pancreas. *Gastroenterology* 1987;92:1153 – 1158.
11. Pettersson M, Ahrén B: Gastrin-releasing peptide (GRP): effects on basal and stimulated insulin and glucagon secretion in the mouse. *Peptides* 1987;8:55 – 60.
12. Hermansen K, Ahrén B: Gastrin-releasing peptide stimulates the secretion of insulin, but not that of glucagon or somatostatin, from the isolated perfused dog pancreas. *Acta Physiologica Scandinavica* 1990;138:175 – 179.
13. Karlsson S, Sundler F, Ahrén B: Insulin secretion by gastrin-releasing peptide in mice: ganglionic versus direct islet effect. *American Journal of Physiology* 1998;274:E124 – 129.
14. Karlsson S, Ahrén B: Cytosolic Ca^{2+} oscillations by gastrin-releasing peptide in single HIT-T15 cells. *Peptides* 1999;230:579 – 587.
15. Karlsson S, Ahrén B: Gastrin-releasing peptide mobilizes calcium from intracellular stores in HIT-T15 cells. *Peptides* 1996; 17:909 – 916.
16. Persson K, Pacini G, Ahrén B: Islet function phenotype in gastrin-releasing peptide receptor gene deficient mice. *Endocrinology* 2002;143:3717–3726.
17. Persson K, Gingerich RL, Nayak S, et al.: Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor deleted mice. *American Journal of Physiology* 2000; 279:E956 – 962.
18. Mutt V: Vasoactive intestinal polypeptide and related peptides. Isolation and chemistry. *Annals of the N Y Academy of Sciences* 1988;527:1 – 19.
19. Bishop AE, Polak JM, Grenl C, et al.: The location of VIP in the pancreas of man and rat. *Diabetologia* 1980;18:73 – 78.
20. Havel PJ, Dunning BE, Verchere CB, et al.: Evidence that vasoactive intestinal polypeptide is a parasympathetic neurotransmitter in the endocrine pancreas in the dog. *Regulatory Peptides* 2004; 71:163 – 170.
21. Winzell MS, Ahrén B: Role of VIP and PACAP in islet function. *Peptides* 2007;28:1805 – 1813.
22. Kato I, Suzuki Y, Akabane A, et al.: Transgenic mice overexpressing human vasoactive intestinal peptide (VIP) gene in pancreatic beta cells. Evidence for improved glucose tolerance and enhanced insulin secretion by VIP and PHM-27 *in vivo*. *The Journal of Biological Chemistry* 1994;269:21223 – 21228.
23. Harmar AJ, Fahrenkrug J, Gozes I, et al.: Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. *British Journal of Pharmacology* 2012;166:4 – 17.
24. Filipsson K, Sundler F, Hannibal J, Ahrén B: PACAP and PACAP receptors in insulin producing tissues: localization and effects. *Regulatory Peptides* 1998;74:167 – 175.
25. Straub SG, Sharp GW: A wortmannin-sensitive signal transduction pathway is involved in the stimulation of insulin release by vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide. *The Journal of Biological Chemistry* 1996;271:1660 – 1668.
26. Filipsson K, Kvist Reimer M, Ahrén B: The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function. *Diabetes* 2001;50:1959 – 1969.
27. Filipsson K, Tornøe K, Holst JJ, Ahrén B: Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans. *Journal of Clinical Endocrinology & Metabolism* 1997;82:3093 – 3098.
28. Jørgensen T, Persson K, Bertrand G, et al.: PAC1 receptor deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. *Journal of Clinical Investigation* 2000;105:1307 – 1315.
29. Persson K, Ahrén B: The neuropeptide PACAP contributes to the glucagon response to insulin-induced hypoglycaemia in mice. *Acta Physiologica Scandinavica* 2002;175:25 – 28.

30. Dunning BE, Taborsky GJ, Jr.: Galanin: sympathetic neurotransmitter in endocrine pancreas? *Diabetes* 1988;37:1157 – 1162.
31. Ahrén B, Veith RC, Taborsky GJ, Jr.: Sympathetic nerve stimulation versus pancreatic noradrenaline infusion in the dog: 1) Effects on basal release of insulin and glucagon. *Endocrinology* 1987; 121:323 – 331.
32. Ahrén B, Lindskog S: Galanin and the regulation of islet hormone secretion. *International Journal of Pancreatology* 1992;11:147 – 160.
33. Parker EM, Izzarelli DG, Nowak MP, et al.: Cloning and characterization of the rat GALR1 galanin receptor from RIN 14B insulinoma cells. *Molecular Brain Research* 1995;34:179 – 189.
34. Lindskog S, Ahrén B: Studies on the mechanism by which galanin inhibits insulin secretion in islets. *European Journal of Pharmacology* 1991;205:21 – 27.
35. Cheng H, Straub SG, Sharp GW: Protein acylation in the inhibition of insulin secretion by norepinephrine, somatostatin, galanin and PGE₂. *American Journal of Physiology* 2003;285:E287 – 294.
36. Dunning BE, Karlsson S, Ahrén B: Contribution of galanin to stress-induced impairment of insulin secretion in swimming mice. *Acta Physiologica Scandinavica* 1991;143:145 – 152.
37. Ahrén B, Pacini G, Wynick D, et al.: Loss-of-function mutation of the galanin gene is associated with perturbed islet function in mice. *Endocrinology* 2004;145:190 – 196.
38. Lindskog S, Ahrén B, Land T, et al.: The novel high-affinity antagonist, galantide, blocks the galanin-mediated inhibition of glucose-induced insulin secretion. *European Journal of Pharmacology* 1992; 210:183 – 188.
39. Pettersson M, Ahrén B, Lundquist I, et al.: Intrapancreatic neuronal localization and effects on insulin secretion in the mouse. *Cell Tissue Research* 1987;248:43 – 48.
40. Sheikh SP, Holst JJ, Skak-Nielsen T, et al.: Release of NPY in pig pancreas: dual parasympathetic and sympathetic regulation. *American Journal of Physiology* 1988;255:G46 – 54.
41. Morgan DG, Kulkarni RN, Hurley JD, et al.: Inhibition of glucose-stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH insulinoma cells. *Diabetologia* 1998;41:1482 – 1491.
42. Wang ZL, Bennet WM, Wang RM, et al.: Evidence of a paracrine role of neuropeptide Y in the regulation of insulin release from pancreatic islets of normal and dexamethasone treated rats. *Endocrinology* 1994;135:200 – 206.
43. Imai Y, Patel HR, Hawkins EJ, et al.: Insulin secretion is increased in pancreatic islets of neuropeptide Y-deficient mice. *Endocrinology* 2007;148:5716 – 5723.
44. Karlsson S, Sundler F, Ahrén B: Neonatal capsaicin treatment in mice: effects on pancreatic peptidergic nerves and 2-deoxy-D- glucose-induced insulin and glucagon secretion. *Journal of the Autonomic Nervous System* 1992;39:51 – 60.
45. Ahrén B, Pettersson M: Calcitonin gene-related peptide (CGRP) and amylin and the endocrine pancreas. *International Journal of Pancreatology* 1990;6:1 – 15.
46. Karlsson S, Scheurink AJW, Steffens AB, Ahrén B: Involvement of capsaicin-sensitive nerves in regulation of insulin secretion and glucose tolerance in conscious mice. *American Journal of Physiology* 1994;267:R1071 – 1077.
47. Gram DX, Ahrén B, Nagy I, et al.: Capsaicin-sensitive sensory fibers in the islets of Langerhans contribute to defective insulin secretion in Zucker diabetic rat, an animal model for some aspects of human type 2 diabetes. *European Journal of Neuroscience* 2007;25: 213 – 223.
48. Wimalawansa SJ: Amylin, calcitonin gene-related peptide, calcitonin and adrenomedullin: a peptide superfamily. *Critical Reviews in Neurobiology* 1997;11:167 – 239.
49. Martinez A, Kapas S, Miller MJ, et al.: Coexpression of receptors for adrenomedullin, calcitonin gene-related peptide, and amylin in pancreatic β -cells. *Endocrinology* 2000;141:406 – 411.
50. Satake H, Kawada T: Overview of the primary structure, tissue- distribution, and functions of tachykinins and their receptors. *Current Drug Targets* 2006;7:963–974.
51. Schmidt PT, Tornøe K, Poulsen SS, et al.: Tachykinins in the porcine pancreas: potent exocrine and endocrine effects via NK-1 receptors. *Pancreas* 2000;20:241 – 247.
52. Brown M, Vale W: Effects of neurotensin and substance P on plasma insulin, glucagon and glucose levels. *Endocrinology* 1978; 99:819 – 822.
53. Lundquist I, Sundler F, Ahrén B, et al.: Somatostatin, pancreatic polypeptide, substance P, and neurotensin: cellular distribution and effects on stimulated insulin secretion in the mouse. *Endocrinology* 1979;104:832 – 838.
54. Adeghate E, Oinery AS, Pallot DJ, Singh J: Distribution of vasoactive intestinal polypeptide, neuropeptide-Y and substance P and their effects on insulin secretion from the in vitro pancreas of normal and diabetic rats. *Peptides* 2001;22:99 – 107.
55. Ponery AS, Adeghate E: Distribution of NPY and SP and their effects on glucagon secretion from the in vitro normal and diabetic pancreatic tissues. *Peptides* 2000;21:1503 – 1509.
56. Maggio CA: The mammalian tachykinin receptors. *General Pharmacology* 1995;26:911 – 944.
57. Persson-Sjögren S, Lejon K, Holmberg D, Forsgren S: Expression of the NK-1 receptor on islet cells and invading immune cells in the non-obese diabetic mouse. *Journal of Autoimmunity* 2005;24:269 – 279.
58. Havel PJ, Ahrén B: Activation of autonomic nerves and the adrenal medulla contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women. *Diabetes* 1997;46:801 – 807.
59. Weyer C, Salbe AD, Lindsay RC, et al.: Exaggerated pancreatic polypeptide secretion in Pima Indians: can an increased parasympathetic drive to the pancreas contribute to hyperinsulinemia, obesity and diabetes in humans? *Metabolism* 2001;50:223 – 230.
60. Ahrén B, Pacini G: Islet adaptation to insulin resistance: mechanisms and implications for interventions. *Diabetes, Obesity and Metabolism* 2005;7:2 – 8.
61. Ahrén B: Evidence that autonomic mechanisms contribute to the adaptive increase in insulin secretion during dexamethasone-induced insulin resistance in humans. *Diabetologia* 2008;51: 1018 – 1024.

62. Yada T, Sakurada M, Filipsson K, et al.: Intraperitoneal PACAP administration decreases blood glucose in GK rats, and in normal and high-fat diet mice. *Annals of the N Y Academy of Sciences* 2000;921:259 – 263.
63. Nakata M, Shintani N, Hashimoto H, et al.: Intra-islet PACAP protects pancreatic β -cells against glucotoxicity and lipotoxicity. *Journal of Molecular Neuroscience* 2010;42:404–410.
64. Ma Y, Ma M, Dai Y, Hong A: Expression, identification and biological effects of a novel VPAC2-specific agonist with high stability and bioactivity. *Acta Biochimica et Biophysica Sinica* 2010;42:21–29.
65. Pan CQ, Li F, Tom I, et al.: Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo. *Journal of Pharmacology and Experimental Therapeutics* 2007; 320:900 – 906.
66. Yu R, Zhang H, Huang L, et al.: Anti-hyperglycemic, antioxidant and anti-inflammatory effects of VIP and VPAC1 agonist on streptozotocin-induced diabetic mice. *Peptides* 2011;32:216–222.
67. Rosengren AH, Jokubka R, Tojjar D, et al.: Overexpression of α 2A-adrenergic receptors contributes to type 2 diabetes. *Science* 2010;327:217–220.